mohammed moneer from lancaster university thank you so much sang froid. now to some other stories making news around the world at this hour german chancellor angela merkel says the current coronavirus restrictions won't get the country through the winter she's pushing pushing for a just decision on tougher restrictions before the christmas holidays and the state of bavaria is already tightening measures asking people to stay at home with only a few exceptions. u.s. president elect joe biden will nominate retired general lloyd austin to be a secretary of the defense that's according to a number of us media reports austin would be the 1st african-american to lead the pentagon after a 41 year army career austin is now on the board of raytheon one of america's biggest weapons firms grammont in new zealand and inquiry into last year's christchurch mosques attack found that security services had not focused enough on the threat from right wing terror the 800 page report said 7 by agencies that placed an inappropriate focus on islamic extremism before the attack

earlier we spoke to viral or just mohammed moneer from britain's lancaster university we asked him whether there are concerns that vaccines could be less effective on the new strain of the virus but i just want to highlight is that when vaccine work vaccine doesn't work against one part of the virus it works against different components of the virus for example there are more than 2030 different sites within the spike but again yes with the vaccine is effective so if one or 2 mutations are still the other one would protect against the infection so as it stands now the move haitians are we have identified it in the you you have literally no impact on to the vaccine effectiveness so therefore the vaccine being developed by the pfizer midden or astra zeneca would have no impact on to the this why i said it would carry on raising the immunity enough to really know if this waras that was viral or just muhammad moneer speaking to us a little bit earlier let's take a look at some other stories making headlines another deadline has passed in post breck's a trade deal to go see asians as the u.k. a

munir who's of ronan just lancaster university there and he joins us on skype from lancaster mohammed moneer welcome to the program so what's your sense of the speed of u.k. approval do you think it's been a bit too fast. well i think. he has a range of experiences in approving the vaccines not only for the folks at 19 but also for from influenza well you know measles and old m.m.r. vaccine so i think the the information they have bought has not just been arrived there is they're being getting access to that out from the tumor and the last year that they would see it was on 23rd of november. to get it going that it's a medicine i didn't see severe for i think they have full talling to go to all the files and to that one by one and to really make assurance that it is safe and it is quality and it is the effective vaccine that need to get into the human elements ok bought the problem is this whole questioning of the speed of approval is going to undermine public confidence and then to the people of the not going to want to take the vaccine. yes certainly that is adamant health has a tendency a

all right let's get some insight into what all of this means we have mohamed moneer with us he's a viral legist at lancaster university in england mohamad good to see you a good to have you back on the program so we just heard the c.e.o. of bio on tech there telling you that he is confident that his vaccine in its existing form can be effective against this new virus strain but he cannot be entirely sure given that information do you think that vaccinations could should still go on. yes absolutely one of the prime reason is that this new variant would not really don't provide the vaccine i think is he is that the mutation that we have seen within the spike that the one that makes the cone chip structure on the surface of the widest those are very few compared to the total length of the protein so the antibody response is already against the entire length of the protein so therefore even one or 2 mutations occurred that's not going to completely made the vaccine ineffective so therefore the vaccines that are approved . don't know.